Laurus Labs

** Shares of India's Laurus Labs LAUL.NS jump 6.1% to 1,168.20 rupees

** Drugmaker reported quarterly revenue from operations at 18.12 billion rupees ($190.92 million), up 5.3% y/y, driven by a richer product mix

** Net profit up ~19.5% y/y

** BOB Capital Markets sees profitability likely improving; raises FY27 and FY28 EPS estimates by 8% and 1%, respectively

** Brokerage expects sales and EBITDA to grow at a CAGR of 15% and 19%, respectively

** Trading vols at 3 mln shares, vs 30-day avg of 1.8 mln shares

** LAUL rated "hold" on average by 13 analysts, median PT: 1,045 rupees - data compiled by LSEG

** YTD, stock up ~4.8%

($1 = 94.9100 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

April 30 (Reuters) - Laurus Labs Ltd LAUL.NS:

• MARCH-QUARTER CONSOL NET PROFIT 2.79 BILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 18.12 BILLION RUPEES

• DECLARES DIVIDEND OF 1.2 RUPEES PER SHARE

Source text: [ID:]

Further company coverage: LAUL.NS

(([email protected];))

Jan 23 (Reuters) - Laurus Labs Ltd LAUL.NS:

• DEC-QUARTER CONSOL NET PAT 2.52 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 17.78 BILLION RUPEES

Further company coverage: LAUL.NS

(([email protected];))

Rewrites, updates shares, adds analysts' comments

By Ananta Agarwal and Rishika Sadam

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2% on Friday after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented drugs, effective Oct. 1.

The U.S. is India's largest market for pharmaceutical exports, accounting for over a third of the total volume, mostly of cheaper generic drugs.

Of the 20 index constituents, 18 traded in the red as of 2:37 p.m. IST.

Analysts described the decline as "sentimental", noting that India's exports to the U.S. are primarily generic medicines, which may not be affected by the tariffs.

Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue and the heaviest stock on the index, fell about 3%. Sun Pharma markets patented drugs, including Ilumya, a psoriasis treatment approved by the U.S. FDA.

The company also has a contract manufacturing unit through EU partners for specialty drugs, where a 15% tariff applies to EU exports to the U.S., according to Vishal Manchanda, equity analyst at Systematix Group.

"The impact on Sun is not very meaningful," he said. "It may be between 1% to 3% of EBITDA."

Laurus Labs LAUL.NS declined the most among constituents of the index, down about 6%.

"There is a general worry that CDMO (contract drug manufacturing organisations) might be impacted as the U.S. moves manufacturing in-house," Manchanda added.

Biocon, which makes complex biosimilars for cancer treatment and has significant U.S. exposure, is down about 4.6%.

"Uncertainty remains whether complex generics and biosimilars will face future tariffs," ICICI Securities analyst Pankaj Pandey said in a note on Friday.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee and Janane Venkatraman)

(([email protected];))

** Laurus Labs LAUL.NS gains 5.5% to 883.50 rupees

** API maker reports eleven-fold surge in Q1 consol net profit, led by strong demand for its active ingredients for generic drugs and in contract manufacturing (CDMO) business

** EBITDA margins expand to 24.8% from year-ago 14.3%, which LAUL attributed to ramp-up in CDMO projects

** Goldman Sachs says CDMO business "going from strength to strength," citing the more-than-double jump in CDMO revenue

** Raises FY26-28 EPS estimates by 3%-22% to factor in faster topline growth; ups PT to 675 rupees from 600 rupees

** Stock rated "hold" on avg; median PT is 650 rupees, per data compiled by LSEG

** LAUL gains ~47% YTD

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Laurus Labs LAUL.NS fall as much as 6%, last down 2.8% at 627 rupees

** On the day, Nifty pharma index .NIPHARM down 2.6% amid broader market decline driven by geopolitical concerns

** Co's Q4 earnings beat estimates, but analysts flag weaknesses

** Bob Capital Markets flags decline in sales of active pharmaceutical ingredients (API), expects generics API, which make up 40% of sales, to decline at 8% CAGR during FY25-27

** Adds, 25% core profit margin lower than industry peers, who operate at 35% and above

** Jefferies maintains 'underperform', adds ~13% y/y growth in co's larger anti retrovirus business is a drag on momentum, with the smaller contract drug manufacturing business Q4 growth at 95% y/y

** Laurus, rated 'hold' on average by analysts, per data compiled by LSEG, up 45% in the last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

April 24 (Reuters) - Laurus Labs Ltd LAUL.NS:

• MARCH-QUARTER CONSOL NET PROFIT 2.34 BILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 17.2 BILLION RUPEES

Source text: [ID:]

Further company coverage: LAUL.NS

(([email protected];;))

April 15 (Reuters) - Laurus Labs Ltd LAUL.NS:

• RECEIVES EIR FROM USFDA FOR API FACILITY

Source text: ID:nBSE4KYwfH

Further company coverage: LAUL.NS

(([email protected];;))

Adds analyst comments in paragraphs 11-12, updates share moves throughout

By Manas Mishra and Ananta Agarwal

April 9 (Reuters) - Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific reciprocal tariffs took effect, leading to more pain in global markets.

Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs last week — but his administration has since indicated that levies on the sector, which in the past has been excluded from such actions, are coming.

The U.S. president has said the tariffs will incentivize drug companies to move operations to the United States. However, analysts and companies have raised concerns about the difficulty in setting up manufacturing in the country.

Shares of major U.S. drugmakers Amgen AMGN.O, AbbVie ABBV.N, Pfizer PFE.N, Merck MRK.N and Eli Lilly LLY.N fell between 3% and 6% in premarket trading.

In Europe, a basket of healthcare stocks .SXDP fell 5% to its lowest since October 2022, leading losses among sectoral indexes on the region-wide STOXX 600 .STOXX, which was down 3.3% at 1013 GMT. The index was heading for its biggest one-day drop since March 2020.

Trump had also threatened the duties on Friday after his first set of "reciprocal" tariffs exempted pharma products. Trump has not said when and by how much he plans to raise levies on pharma imports.

"While the details are scant, we are strongly opposed to tariffs on any pharmaceuticals — these will likely do little to shift manufacturing back to the U.S.," said BMO Capital Markets analyst Evan Seigerman.

"Given the complexity of the pharma supply chain, we do not expect the industry to make any major changes. These current tariffs are being pursued under emergency powers, which at worse will last until the end of the current administration and could end sooner with an act of Congress."

Seigerman also pointed to concerns over recent layoffs at the U.S. Food and Drug Administration, saying the worries were now compounded by the "real talk" of pharma tariffs.

ADDITIONAL COSTS, LONG WAIT FOR PRODUCTION

Europe and the U.S. have interconnected supply chains for medicines. The United States depends on medicines partly produced in Europe that bring in hundreds of billions of dollars in revenue.

Bernstein analyst Courtney Breen wrote in a note that her worst-case scenario assumes tariffs could be steep, leading to about $53 billion in additional costs paid for pharmaceutical imports.

If companies did choose to bring new manufacturing to the United States, Breen expects additional spend of $2 billion for each new "green field" site and a five-year runway to production.

EU medical and pharmaceutical product exports to the U.S. totaled about 90 billion euros ($97 billion) in 2023, according to latest Eurostat data.

Shares of AstraZeneca AZN.L, GSK GSK.L, Roche ROG.S, Sanofi SASY.PA and Novartis NOVN.S fell between 5% and 6.5% in Europe. Meanwhile, Indian pharmaceutical stocks .NIPHARM closed nearly 2% lower, dragging down the benchmark Nifty 50 .NSEI by 0.6%.

IPCA Laboratories IPCA.NS, Glenmark Pharma GLEN.NS and Biocon BION.NS were the top losers by percentage on the pharma index in Mumbai, ending the trading session between 4% and 5.5% lower.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. The United States accounts for a third of India's overall pharma exports.

(Reporting by Kashish Tandon, Ananta Agarwal and Manas Mishra in Bengaluru and Anna Pruchnicka in Gdansk; Editing by Savio D'Souza, Mrigank Dhaniwala and Shounak Dasgupta)

(([email protected]))

March 28 (Reuters) - Laurus Labs Ltd LAUL.NS:

• LAURUS LABS LTD - TO ACQUIRE 26% STAKE IN KURNOOL RENEWABLES

• LAURUS LABS LTD - INVESTMENT IN KURNOOL RENEWABLES UP TO 350 MILLION RUPEES

Source text: ID:nBSE3GFqcv

Further company coverage: LAUL.NS

(([email protected];;))

March 6 (Reuters) - Laurus Labs Ltd LAUL.NS:

• APPROVES 833 MILLION RUPEES INVESTMENT IN KRKA PHARMA

• TO ACQUIRE 83.3 MILLION EQUITY SHARES IN KRKA PHARMA

• KRKA D.D. TO INVEST 867 MILLION RUPEES IN KRKA PHARMA

Source text: ID:nNSE2b3B2q

Further company coverage: LAUL.NS

(([email protected];;))

Jan 27 (Reuters) - Laurus Labs Ltd LAUL.NS:

• LAURUS LABS - IF THERE IS FUNDING CHALLENGE, IT WILL NOT AFFECT MEDICATION PROCUREMENT

• LAURUS LABS - BELIEVES THERE WILL NOT BE SIGNIFICANT IMPACT ON BUSINESS

• LAURUS LABS - CLARIFIES REPORT "US PRESIDENT FROZE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF"

Source text: ID:nBSE1nv6WJ

Further company coverage: LAUL.NS

(([email protected];))

Jan 24 (Reuters) - Laurus Labs Ltd LAUL.NS:

• DEC-QUARTER CONSOL NET PROFIT 923 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 14.15 BILLION RUPEES

Source text: [ID:]

Further company coverage: LAUL.NS

(([email protected];;))

Jan 22 (Reuters) - Laurus Labs Ltd LAUL.NS:

• US FDA ISSUED ONE OBSERVATION FOR FOREIGN SUBSIDIARY OF LAURUS LABS

• OBSERVATION ISSUED AFTER POST-MARKETING ADVERSE DRUG EXPERIENCE INSPECTION BY US FDA

Source text: ID:nBSEb7YxX3

Further company coverage: LAUL.NS

(([email protected];;))

Dec 20 (Reuters) - Laurus Labs Ltd LAUL.NS:

• LAURUS LABS - EIGHT ROADS VENTURES, F-PRIME CAPITAL INVEST RUPEES 1.20 BILLION IN LAURUS BIO

Source text: ID:nBSEc2sfxT

Further company coverage: LAUL.NS

(([email protected];))

Dec 6 (Reuters) - Laurus Labs Ltd LAUL.NS:

• APPROVED INVESTMENT OF 400 MILLION RUPEES IN LAURUS BIO

• APPROVED EXECUTION OF AGREEMENTS WITH EIGHT ROADS VENTURES AND F-PRIME CAPITAL

• DEAL WITH EIGHT ROADS VENTURES AND F-PRIME CAPITAL FOR INVESTMENT OF 1.2 BILLION RUPEES

• SHAREHOLDING OF INVESTORS AND CO IN UNIT SHALL BE 13.73% AND 74.64%, RESPECTIVELY

• CO AND INVESTORS WILL HAVE RIGHT TO INVEST ADDITIONAL UP TO 350 MILLION RUPEES IN UNIT

Source text: ID:nNSE3SYffn

Further company coverage: LAUL.NS

(([email protected];;))

** Shares of Glenmark Life Sciences GLEM.NS drop 10% to 936.90 rupees

** Stock set for worst day ever if losses hold

** API maker's Q2 profit fell ~20% YoY, rev from ops down ~15% YoY

** GLEM said temporary closure of a manufacturing facility in Gujarat hurt revenue across geographies

** Trading volume at 2.1x the 30-day moving avg

** Analysts' avg rating on GLEM at "buy"; peers Laurus Labs LAUL.NS and Divi's Laboratories DIVI.NS rated "hold" - LSEG data

** GLEM's 43% YTD gain bigger than LAUL's ~10% climb but smaller than DIVI's ~48% rise

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Oct 24 (Reuters) - Laurus Labs Ltd LAUL.NS:

• LAURUS LABS SEPT-QUARTER CONSOL NET PROFIT 198.4 MILLION RUPEES

• LAURUS LABS SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.24 BILLION RUPEES

Source text for Eikon: ID:nnAZN2HZ9PK

Further company coverage: LAUL.NS

(([email protected];))

Sept 13 (Reuters) - Laurus Labs Ltd LAUL.NS:

• CONCLUDES USFDA AUDIT FOR API MANUFACTURING FACILITY AT HYDERABAD

• USFDA AUDIT COMPLETED WITHOUT ANY 483 OBSERVATION.

Source text for Eikon: ID:nBSEbR9x4Z

Further company coverage: LAUL.NS

(([email protected];))

July 25 (Reuters) - Laurus Labs Ltd LAUL.NS:

• JUNE-QUARTER CONSOL NET PROFIT 125.1 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: LAUL.NS

(([email protected];))

May 30 (Reuters) - Willow Biosciences Inc WLLW.TO:

• WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS

• WILLOW BIOSCIENCES INC - MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS

Source text for Eikon: ID:nCNWNDb52a

Further company coverage: WLLW.TO

(([email protected];))

** Shares of Solara Active Pharma Sciences SOLA.NS rise as much as 3.9% before trimming some gains, last up 1.1% to 489.55 rupees

** The active pharmaceutical ingredients (API) maker said its Visakhapatnam facility completes U.S. FDA Inspection with Zero 483 observations

** Including session's gains, stock up 47% YTD, while peers Alembic Pharmaceuticals ALEM.NS and Laurus Labs LAUL.NS have gained 26% and 3.7%, respectively

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

BENGALURU, May 15 (Reuters) - Drugmaker Granules India GRAN.NS posted a 1.6% fall in fourth-quarter revenue on Wednesday, hurt by a decline in paracetamol sales and price erosion.

The company's consolidated revenue fell year-on-year to 11.76 billion rupees (nearly $141 million) for the three months to March 31.

Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug's API as well as the finished dosage - the ready-for-consumption product.

Still, weak sales of the drug and price erosion due to heightened competition hurt its revenue. This is despite analysts expecting Indian API makers, including Granules, to benefit from increasing demand from Europe and the U.S., the industry's biggest markets.

Shares fell as much as 2.6% after it reported its results.

Rivals Glenmark Life Sciences GLEM.NS and Laurus Labs LAUL.NS posted lower fourth-quarter profits.

Glenmark's revenue was hit by issues stemming from the Red Sea crisis while Laurus was challenged by multiple factors including a decline in selling prices of antiretroviral products.

A 9.5% drop in Granules' raw material expenses, meanwhile, helped its quarterly profit climb 8.4% to 1.30 billion rupees.

API makers use a variety of chemicals in their formulations, including hydrochloric acid and chloroform, accounting for a majority of the drug-makers' input costs.

The easing costs had helped its profit marginally climb in the third quarter as well, before which profit fell for two straight quarters.

($1 = 83.4750 Indian rupees)

(Reporting by Varun Hebbalalu in Bengaluru; Editing by Janane Venkatraman )

(([email protected];))

** Shares of Laurus Labs LAUL.NS close 2% lower to 425.9 rupees

** Co's March-qtr profit fell roughly 26.6% YoY, its fifth straight quarterly profit drop

** Rival Glenmark Life Sciences GLEM.NS also posted Q4 profit drop on the day; its stock dropped after results

** Analysts' avg rating on LAUL stock is "hold", and is "buy" on GLEM - LSEG data

** LAUL flips to YTD loss, down 1% so far this year; GLEM up 18% from last year

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

April 19 (Reuters) - Laurus Labs Ltd LAUL.NS:

• USFDA COMPLETED INSPECTION OF OUR API MANUFACTURING FACILITIES UNIT–1 AND UNIT–3,ANAKAPALLI

• THE INSPECTION WAS SUCCESSFULLY CLOSED WITHOUT ANY 483 OBSERVATIONS

Source text for Eikon: [ID:]

Further company coverage: LAUL.NS

(([email protected];))

** Shares of contract research firm Syngene International SYNN.NS up 2.1% and pharmaceuticals firm Neuland Laboratories NEUL.NS up 4.8%

** Goldman Sachs initiates stocks with a 'buy' rating, sets street-high PTs of 875 rupees for SYNN and 9,100 rupees for NEUL; highlights improving funding for biotech, capacity ramp-up and new contract wins

** Brokerage believes India's share in global contract research/drug manufacturing will rise as companies reduce dependence on China; lists SYNN, NEUL as its top picks in sector

** "Any progress" on U.S. bill that prohibits federal agencies from contracting with China biotech companies/service providers, "could bring in disproportionate benefits" to NEUL - Goldman

** Meanwhile, shares of Laurus Labs LAUL.NS down 1.7% after brokerage initiates stock with "sell"

** NEUL up 23.5% so far this year, vastly outperforming LAUL's 5% rise and SYNN's 8.9% growth

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of pharmaceutical firm Laurus Labs LAUL.NS rise as much as 7.9% to 448 rupees, highest since Nov. 28, 2022

** Stock on track for fourth consecutive session of gains

** Reuters could not immediately ascertain a reason for the move

** Stock top gainer in Nifty pharma index .NIPHARM, which is trading flat

** Stock most active since Jan. 25; more than 6.9 mln shares change hands by 1:59 p.m. IST, 3.9x the 30-day avg

** Avg rating of 10 analysts equivalent of "hold", median PT is 333 rupees - LSEG data

** Among peers, Granules India GRAN.NS rated "strong buy" while Glenmark Life Sciences GLEM.NS is rated "buy" - LSEG

** LAUL fell 8.8% in March quarter vs 12.9% rise in Nifty pharma index

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Laurus Labs LAUL.NS fall as much as 10% to 361 rupees, lowest level since Nov. 2

** LAUL said on Wednesday its consol net profit fell ~89% to 231.4 mln rupees ($2.8 mln)

** Co's consol net profit has fallen between 55% and 90% in the last four quarters

** Antique Stock Broking cuts PT to 333 rupees from 376 rupees, retains "hold"

** Says despite expected improvement in margins, unlikely to grow beyond 21%–22% in FY25

** More than 13.2 mln shares change hands, 6.1x its 30-day avg; on track for most active trading session since Oct. 23

** Average rating of 9 analysts covering LAUL is "hold"; stock currently trading at ~7% premium to median PT of 340 rupees - LSEG data

** Stock has fallen over 14% so far in January

($1 = 83.1300 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Jan 24 (Reuters) - Laurus Labs Ltd LAUL.NS:

• LAURUS LABS LTD DEC-QUARTER CONSOL NET PROFIT 231.4 MILLION RUPEES VERSUS 2.03 BILLION RUPEES

• LAURUS LABS LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES VERSUS 15.45 BILLION RUPEES

Source text for Eikon: ID:nBSE1JFWQf

Further company coverage: LAUL.NS

(([email protected];))

** Shares of Laurus Labs LAUL.NS fall as much as 3.1% to 376.05 rupees, their steepest intraday pct decline since Oct 23

** Co said on Tuesday its facility in the Andhra Pradesh state was issued five observations from the U.S. FDA

** Laurus stock dropped 3% at least six times this year

** Stock lost 9.6% after Sept-qtr results

** Since then, stock recovered 7% of its value until Tuesday's close

** Mean rating of nine analysts is "hold"; median PT is 340 rupees, 11% lower than current price - LSEG data

** Stock up 1.7% YTD, compared with the broader Nifty Pharma .NIPHARM index's 27% climb

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))